Editorial
Trastuzumab in the Treatment of Breast Cancer
N Engl J Med 2005; 353:1734-1736October 20, 2005
- Article
Two articles in this issue of the Journal report on the considerable therapeutic benefit of trastuzumab, a monoclonal antibody, in primary breast cancer, as measured by reductions in the rates of both recurrence and death.1,2 These reports, which complete the bench-to-bedside cycle, are elegant examples of translational research. The human epidermal growth factor receptor 2 (HER2) is a member of the epidermal growth factor receptor (EGFR) family of transmembrane tyrosine kinases and is normally involved in the regulation of cell proliferation. The HER2 gene, located on the short arm of chromosome 17, was discovered and cloned in 1983 and found to be related to, albeit distinct from, the EGFR.3 Amplification (an excess number of gene copies) or overexpression (excess production of protein) confers on the affected cancer cell aggressive behavioral traits, including enhanced growth and proliferation, increased invasive and metastatic capability, and stimulation of angiogenesis.
Patients with breast cancer in which HER2 is amplified or HER2 is overexpressed are likely to have poorly differentiated tumors with a high proliferative rate, positive axillary lymph nodes, and decreased expression of estrogen and progesterone receptors. These characteristics are associated with an increased risk of disease recurrence and death.4 The observation by Sato et al. that a monoclonal antibody against the EGFR inhibited binding of the natural ligand (EGF) to the receptor and inhibited receptor phosphorylation and signaling5 encouraged scientists at Genentech to develop a mouse monoclonal antibody with high affinity for the extracellular domain of the HER2 transmembrane protein. The humanized version of this antibody is trastuzumab — a molecularly engineered antibody that was produced by inserting portions of the antigen-binding site of the murine antibody into a human monoclonal antibody.6
Over the ensuing decade, trastuzumab was found to produce objective regressions in 11 to 26 percent of patients with metastatic disease without undue toxic effects. Patients who had tumors in which HER2 amplification was detected by fluorescence in situ hybridization (FISH) (thus, FISH-positive tumors) or tumors that showed overexpression of HER2 (a result on immunohistochemical analysis of 3+) had a response rate of 34 percent after treatment with trastuzumab alone.
Trastuzumab combined with cytotoxic agents commonly used in the management of metastatic breast cancer, especially taxanes, vinorelbine, and platinum salts, also gave encouraging results. Preclinical studies had suggested that substantial additive and sometimes synergistic effects could be expected from these combinations.7 These rationally developed trastuzumab combinations were taken to clinical trials. Two phase 3 trials compared first-line chemotherapy alone with the combination of chemotherapy with trastuzumab in patients with HER2 overexpression in metastatic breast cancer. In the trastuzumab group there was a dramatic improvement in all therapeutic end points — time to progression, response rate, duration of response, and survival.8,9 An unexpected observation in these phase 3 trials was the development of congestive heart failure in 2 to 16 percent of the patients who were treated with trastuzumab and chemotherapy; the frequency was highest among patients receiving anthracycline and trastuzumab simultaneously.8 The addition of platinum salts significantly enhanced the efficacy of the taxane–trastuzumab doublet, and this triple-drug combination provides optimal palliation to patients with HER2-positive metastatic breast cancer.10
The adverse prognosis of HER2-positive breast cancer led to the development of clinical trials to assess the efficacy and safety of trastuzumab in patients with primary breast cancer. Although there was concern about the possibility of inducing long-term cardiac dysfunction with this agent, experience in the metastatic setting suggested that cardiac dysfunction was potentially reversible. Because of the high risk of recurrence and death in HER2-positive breast cancer, a rate of congestive heart failure of no more than 4 percent above that without trastuzumab was considered acceptable.
Four large multicenter trials were designed to test the role of trastuzumab as adjuvant therapy after surgical treatment of primary breast cancer. The results of three of these trials (the combined results of the National Surgical Adjuvant Breast and Bowel Project trial [B-31] and the North Central Cancer Treatment Group trial [N9831] and those of the Herceptin Adjuvant [HERA] trial) are reported in this issue of the Journal.1,2 The results are simply stunning. With very brief follow-up (one to two and a half years), all three trials show highly significant reductions in the risk of recurrence, of a magnitude seldom observed in oncology trials. In fact, only tamoxifen administered for five years to patients with estrogen-receptor–positive primary breast cancer produces a 50 percent reduction in the risk of recurrence. Many recent phase 3 trials of adjuvant systemic therapy for breast cancer highlighted absolute benefits of 2 to 6 percent after four to six years of follow-up. In contrast, an absolute difference of 6 percent is evident in the HERA trial at two years, with a benefit of 8 percent observed in the joint analysis of the trials B-31 and N9831 during the same interval; by four years, these two trials project an absolute benefit of 18 percent, exceeding all previously reported therapeutic benefits in breast cancer.
Survival differences are also emerging from these comparisons. The most dramatic observation in these trials, however, is the comparison of hazard ratios in the joint analysis: the initial peak in recurrences that is generally expected during the first two to three years, and indeed, was observed in the control groups of the two trials, has been abrogated by trastuzumab, and the hazard ratio remains very low even a year after completion of trastuzumab therapy. This observation suggests a dramatic and perhaps permanent perturbation of the natural history of the disease, maybe even a cure. Longer follow-up will determine whether this interpretation is correct.
These results compelled the respective data and safety monitoring committees to stop the trials after the first interim analyses. Trastuzumab was offered to all patients in the control groups. These modifications were clearly appropriate, although they will cloud subsequent analyses and probably result in underestimation of the overall benefit of trastuzumab therapy.
On the basis of these results, our care of patients with HER2-positive breast cancer must change today. Certainly, patients with lymph-node–positive, HER2-positive breast cancer should receive trastuzumab as part of optimal adjuvant systemic therapy, unless the antibody is clearly contraindicated. Patients with negative lymph nodes, whose estimated risk of recurrence after optimal chemotherapy and endocrine therapy comfortably exceeds the risk of the cardiac toxic effects of trastuzumab, should also be offered the antibody. Since most HER2-positive tumors have other adverse prognostic factors, this risk–benefit scenario is likely to apply to many patients with node-negative breast cancer.
Although these trials provide some answers, they also raise many new questions. What is the optimal schedule for therapy with trastuzumab: should it be given simultaneously with or sequentially after chemotherapy? Comparison of trials B-31 and N9831 and the HERA trial suggests that cardiotoxicity is lower after sequential administration. However, we cannot rule out the possibility that simultaneous administration of chemotherapy and trastuzumab is more effective than sequential administration. Preclinical experiments indicate that simultaneous administration is critical to optimal cytotoxic effect, whereas sequential administration results in cytostasis.11 Longer follow-up of the HERA trial and trial N9831 will confirm or refute these preclinical results. If they are confirmed, it may follow that continuation of trastuzumab beyond the completion of chemotherapy is unnecessary — a concept to be tested in future trials.
Although the major results presented in these two reports appear to be identical, there are important differences between the reports that deserve highlighting and that may provide clues to future developments. One third of patients included in the HERA trial had lymph-node–negative breast cancer. This would indicate a better overall prognosis for this patient population. However, the disease-free survival curves of the two reports indicate that both the control group and the trastuzumab group of the combined North American report fared better than the corresponding groups in the HERA trial. It is tempting to hypothesize that this difference is partly explained by differences in the schedule of administration and in the adjuvant chemotherapy regimens used: only 26 percent of the patients in the HERA trial received a taxane, whereas all patients in the combined analysis received paclitaxel.
There are other important questions that can be answered with longer follow-up in these two trials and in future trials. What is the nature and reversibility of cardiac dysfunction? The joint analysis provides reassuring but very preliminary information about symptomatic control of heart failure in the majority of patients. What will be the long-term effects of even treatable congestive heart failure? Will cardiac function normalize in the absence of cardiac medication? Even with the large therapeutic benefits of trastuzumab, avoiding unnecessary toxic effects is an important goal. Assessing the worth of including a group that does not receive anthracyclines, as in another trial (Breast Cancer International Research Group trial 006), will be of critical importance to the design of the next generation of adjuvant trials with trastuzumab.
Clearly, the results reported in this issue of the Journal are not evolutionary but revolutionary. The rational development of molecularly targeted therapies points the direction toward continued improvement in breast cancer therapy. Other targets and other agents will follow. However, trastuzumab and the two reports in this issue will completely alter our approach to the treatment of breast cancer.
- References
References
1
Romond EH ,Perez EA ,Bryant J , et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684
Full Text | Web of Science | Medline2
Piccart-Gebhart MJ ,Procter M ,Leyland-Jones B , et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672
Full Text | Web of Science | Medline3
Schechter AL ,Hung MC ,Vaidyanathan L , et al. The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 1985;229:976-978
CrossRef | Web of Science | Medline4
Slamon DJ ,Clark GM ,Wong SG ,Levin WJ ,Ullrich A ,McGuire WL . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182
CrossRef | Web of Science | Medline5
Sato JD ,Kawamoto T ,Le AD ,Mendelsohn J ,Polikoff J ,Sato GH . Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1983;1:511-529
Medline6
Lewis GD ,Figari I ,Fendly B , et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 1993;37:255-263
CrossRef | Web of Science | Medline7
Pegram M ,Hsu S ,Lewis G , et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999;18:2241-2251
CrossRef | Web of Science | Medline8
Slamon DJ ,Leyland-Jones B ,Shak S , et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792
Full Text | Web of Science | Medline9
Marty M ,Cognetti F ,Maraninchi D , et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 Study Group. J Clin Oncol 2005;23:4265-4274
CrossRef | Web of Science | Medline10
Robert N ,Leyland-Jones B ,Asmar L , et al. Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive advanced breast cancer. Breast Cancer Res Treat 2002;76:Suppl 1:S37-S37 abstract.
CrossRef | Web of Science11
Pietras RJ ,Pegram MD ,Finn RS ,Maneval DA ,Slamon DJ . Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998;17:2235-2249
CrossRef | Web of Science | Medline
- Citing Articles (78)
Citing Articles
1
Gradishar, William J., . (2012) HER2 Therapy — An Abundance of Riches. New England Journal of Medicine 366:2, 176-178
Full Text2
H. Moch, P. R. Blank, M. Dietel, G. Elmberger, K. M. Kerr, J. Palacios, F. Penault-Llorca, G. Rossi, T. D. Szucs. (2011) Personalized cancer medicine and the future of pathology. Virchows Archiv
CrossRef3
Patrick R Brown. (2011) The dark side of hope and trust: Constructed expectations and the value-for-money regulation of new medicines. Health Sociology Review 0:0, 111114202837037-433
CrossRef4
N. Gnaoui, S. Hayah, M. Hassar, R. Saile, H. Benomar. (2011) Récepteurs hormonaux et statut HER2 dans les carcinomes de la glande mammaire. Journal Africain du Cancer / African Journal of Cancer
CrossRef5
Kamal S. Saini, Hatem A. Azim Jr, Otto Metzger-Filho, Sherene Loi, Christos Sotiriou, Evandro de Azambuja, Martine Piccart. (2011) Beyond trastuzumab: New treatment options for HER2-positive breast cancer. The Breast 20, S20-S27
CrossRef6
Javier Cortes, Henri Roché. (2011) Docetaxel combined with targeted therapies in metastatic breast cancer. Cancer Treatment Reviews
CrossRef7
Sukanya Raghavan, Marianne Quiding-Järbrink. (2011) Regulatory T cells in gastrointestinal tumors. Expert Review of Gastroenterology & Hepatology 5:4, 489-501
CrossRef8
Kelli S. Dempsey. (2011) Chemotherapy-Induced Cardiotoxicity in Women. Heart Failure Clinics 7:3, 427-435
CrossRef9
Thor Edvardsen. (2011) Can Modern Echocardiographic Techniques Predict Drug-Induced Cardiotoxicity?
Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology 57:22, 2271-2272
CrossRef10
Stephen Hiscox, Robert I Nicholson. (2011) Src kinase: a therapeutic opportunity in endocrine-responsive and resistant breast cancer. Expert Review of Endocrinology & Metabolism 6:3, 423-435
CrossRef11
D H Roukos. (2011) Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. The Pharmacogenomics Journal 11:2, 81-92
CrossRef12
Thomas Stricker, Daniel V.T. Catenacci, Tanguy Y. Seiwert. (2011) Molecular Profiling of Cancer—The Future of Personalized Cancer Medicine: A Primer on Cancer Biology and the Tools Necessary to Bring Molecular Testing to the Clinic. Seminars in Oncology 38:2, 173-185
CrossRef13
Montserrat Solá, Mireia Margelí, Eva Castellá, Juan F Julian, Miquel Rull, Josep M Gubern, Antonio Mariscal, Agustí Barnadas, Manuel Fraile. (2011) Prognostic value of hematogenous dissemination and biological profile of the tumor in early breast cancer patients: A prospective observational study. BMC Cancer 11:1, 252
CrossRef14
Dimitrios H Roukos. (2010) Next-generation sequencing and epigenome technologies: potential medical applications. Expert Review of Medical Devices 7:6, 723-726
CrossRef15
Ke Liang, Francisco J. Esteva, Constance Albarracin, Katherine Stemke-Hale, Yang Lu, Giampaolo Bianchini, Ching-Yi Yang, Yong Li, Xinqun Li, Chun-Te Chen, Gordon B. Mills, Gabriel N. Hortobagyi, John Mendelsohn, Mien-Chie Hung, Zhen Fan. (2010) Recombinant Human Erythropoietin Antagonizes Trastuzumab Treatment of Breast Cancer Cells via Jak2-Mediated Src Activation and PTEN Inactivation. Cancer Cell 18:5, 423-435
CrossRef16
Christos Katsios, Dimosthenis E. Ziogas, Theodore Liakakos, Odysseas Zoras, Dimitrios H. Roukos. (2010) Translating Cancer Genomes Sequencing Revolution into Surgical Oncology Practice. Journal of Surgical Research
CrossRef17
Christos Katsios, Odysseas Zoras, Dimitrios H Roukos. (2010) Improving women’s health: advances, failures and cancer genome prospects. Women's Health 6:6, 769-772
CrossRef18
Ehud Shahar, Raphael Gorodetsky, Elena Gaberman, Elina Aizenshtein, Jacob Pitcovski. (2010) Targeted microbeads for attraction and induction of specific innate immune response in the tumor microenvironment. Vaccine 28:45, 7279-7287
CrossRef19
Einat Shalom-Paz, Benny Almog, Fady Shehata, Jack Huang, Hananel Holzer, Ri-Cheng Chian, Weon-Young Son, Seang Lin Tan. (2010) Fertility preservation for breast-cancer patients using IVM followed by oocyte or embryo vitrification. Reproductive BioMedicine Online 21:4, 566-571
CrossRef20
Sara Rodriguez-Acebes, Ian Proctor, Marco Loddo, Alex Wollenschlaeger, Mohammed Rashid, Mary Falzon, A. Toby Prevost, Richard Sainsbury, Kai Stoeber, Gareth H. Williams. (2010) Targeting DNA Replication before it Starts. The American Journal of Pathology 177:4, 2034-2045
CrossRef21
P. Maroun, J. Gligorov, J. Ohnona, C. Murariu, Y. Belkacémi. (2010) Détermination de HER2 dans les adénocarcinomes pour établir le pronostic et prédire la réponse aux traitements. Bio tribune magazine 36:1, 30-35
CrossRef22
A.-E. Saliba, L. Saias, E. Psychari, N. Minc, D. Simon, F.-C. Bidard, C. Mathiot, J.-Y. Pierga, V. Fraisier, J. Salamero, V. Saada, F. Farace, P. Vielh, L. Malaquin, J.-L. Viovy. (2010) Microfluidic sorting and multimodal typing of cancer cells in self-assembled magnetic arrays. Proceedings of the National Academy of Sciences 107:33, 14524-14529
CrossRef23
Dimitrios H Roukos. (2010) Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics 11:8, 1039-1043
CrossRef24
P. Maroun, J. Gligorov, J. Ohnona, C. Murariu, Y. Belkacémi. (2010) Détermination de HER2 dans les adénocarcinomes pour établir le pronostic et prédire la réponse aux traitements. Oncologie 12:7, 416-421
CrossRef25
Cristina Oliveras-Ferraros, Alejandro Vazquez-Martin, Begoña Martin-Castillo, Silvia Cufí, Sonia Del Barco, Eugeni Lopez-Bonet, Joan Brunet, Javier A. Menendez. (2010) Dynamic emergence of the mesenchymal CD44posCD24neg/low phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin). Biochemical and Biophysical Research Communications 397:1, 27-33
CrossRef26
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Rosenberg, Eric S., Cort, Alice M., Ebeling, Sally H.Peters, Christine C., Muss, Hyman B., D'Alessandro, Helen Anne, Brachtel, Elena F., . (2010) Case 15-2010. New England Journal of Medicine 362:20, 1921-1928
Full Text27
Daniel Serin. (2010) Cancer du sein avancé ou métastatique HER2+: évolution de la prise en charge. Oncomagazine 4:2, 16-18
CrossRef28
T. Pienkowski, C. C. Zielinski. (2010) Trastuzumab treatment in patients with breast cancer and metastatic CNS disease. Annals of Oncology 21:5, 917-924
CrossRef29
Dimitrios H Roukos. (2010) Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management?. Expert Review of Molecular Diagnostics 10:3, 247-250
CrossRef30
Nathalie Chabbert-Buffet, Catherine Uzan, Joseph Gligorov, Suzette Delaloge, Roman Rouzier, Serge Uzan. (2010) Pregnancy after breast cancer: A need for global patient care, starting before adjuvant therapy. Surgical Oncology 19:1, e47-e55
CrossRef31
Dimitrios H Roukos, Dimosthenis Ziogas. (2010) From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Review of Anticancer Therapy 10:2, 123-128
CrossRef32
Carmen C. Popescu, Ivo A. Olivotto, Wayne A. Beckham, Will Ansbacher, Sergei Zavgorodni, Richard Shaffer, Elaine S. Wai, Karl Otto. (2010) Volumetric Modulated Arc Therapy Improves Dosimetry and Reduces Treatment Time Compared to Conventional Intensity-Modulated Radiotherapy for Locoregional Radiotherapy of Left-Sided Breast Cancer and Internal Mammary Nodes. International Journal of Radiation Oncology*Biology*Physics 76:1, 287-295
CrossRef33
Pankaj G. Roy, Norman Pratt, Colin A. Purdie, Lee Baker, Alison Ashfield, Phil Quinlan, Alastair M. Thompson. (2010) High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer. International Journal of CancerNA-NA
CrossRef34
Kathryn M. Kash, Smiriti Sharma, Neil I. Goldfarb. (2009) Is Disease Management Right for Oncology?. Population Health Management 12:6, 337-343
CrossRef35
Eliyaz Ahamed, Francesco A Mauri, Grant Pakter, Adrian Lim, Justin Stebbing. (2009) Trastuzumab: unusual responses and toxicities. Future Oncology 5:6, 779-784
CrossRef36
J. Gligorov, D. Azria, Y. Belkacemi, M. Spielmann, M. Namer. (2009) La recherche clinique dans le domaine du cancer du sein: état des lieux et perspectives. Oncologie 11:6, 319-324
CrossRef37
Panagiotis Karagiannis, Josef Singer, James Hunt, Samuel K. E. Gan, Sarah M. Rudman, Diana Mechtcheriakova, Regina Knittelfelder, Tracy R. Daniels, Philip S. Hobson, Andrew J. Beavil, James Spicer, Frank O. Nestle, Manuel L. Penichet, Hannah J. Gould, Erika Jensen-Jarolim, Sophia N. Karagiannis. (2009) Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunology, Immunotherapy 58:6, 915-930
CrossRef38
Christina Justenhoven, Christiane B. Pierl, Susanne Haas, Hans-Peter Fischer, Ute Hamann, Christian Baisch, Volker Harth, Anne Spickenheuer, Sylvia Rabstein, Caren Vollmert, Thomas Illig, Beate Pesch, Thomas Brüning, Jürgen Dippon, Yon-Dschun Ko, Hiltrud Brauch. (2009) Polymorphic loci of E2F2, CCND1 and CCND3 are associated with HER2 status of breast tumors. International Journal of Cancer 124:9, 2077-2081
CrossRef39
Christine Desmedt, Jeff Sperinde, Fanny Piette, Weidong Huang, Xueguang Jin, Yuping Tan, Virginie Durbecq, Denis Larsimont, Rosa Giuliani, Colombe Chappey, Marc Buyse, John Winslow, Martine Piccart, Christos Sotiriou, Christos Petropoulos, Michael Bates. (2009) Quantitation of HER2 Expression or HER2:HER2 Dimers and Differential Survival in a Cohort of Metastatic Breast Cancer Patients Carefully Selected for Trastuzumab Treatment Primarily by FISH. Diagnostic Molecular Pathology 18:1, 22-29
CrossRef40
Gabriella Mariani, Angelica Fasolo, Elena De Benedictis, Luca Gianni. (2009) Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nature Clinical Practice Oncology 6:2, 93-104
CrossRef41
X Zhou, Y Yuan, J Song, W Chen, J Li, L Ye, X Meng, D Xia. (2009) Dual silencing of epidermal growth factor and insulin-like growth factor 1 receptors significantly limits growth of nasopharyngeal carcinoma in nude mice. The Journal of Laryngology & Otology 123:02, 208
CrossRef42
Carolyn Straehle, Fatima Cardoso, Evandro Azambuja, Stella Dolci, Livia Meirsman, Kris Vantongelen, Michalis Ignatiadis, Christos Sotiriou, Martine J. Piccart-Gebhart. (2009) Better translation from bench to bedside: Breakthroughs in the individualized treatment of cancer. Critical Care Medicine 37:Supplement, S22-S29
CrossRef43
Toshio Ohashi, Atsuya Takeda, Naoyuki Shigematsu, Junichi Fukada, Naoko Sanuki, Atsushi Amemiya, Atsushi Kubo. (2009) Dose Distribution Analysis of Axillary Lymph Nodes for Three-Dimensional Conformal Radiotherapy With a Field-in-Field Technique for Breast Cancer. International Journal of Radiation Oncology*Biology*Physics 73:1, 80-87
CrossRef44
Laurent Zelek, Paule Latino-Martel, Nathalie Pecollo, Émilie Barrandon, Sébastien Czernichow, Pilar Galan, Serge Hercberg. (2008) Nutrition et prévention tertiaire des cancers. y a-t-il des recommandations ?. Cahiers de Nutrition et de Diététique 43:5, 235-241
CrossRef45
Abby Siegel. (2008) Moving Targets in Hepatocellular Carcinoma: Hepatic Progenitor Cells as Novel Targets for Tyrosine Kinase Inhibitors. Gastroenterology 135:3, 733-735
CrossRef46
John C. Mansour, Roderich E. Schwarz. (2008) Molecular Mechanisms for Individualized Cancer Care. Journal of the American College of Surgeons 207:2, 250-258
CrossRef47
Augusto Villanueva, Sara Toffanin, Josep M Llovet. (2008) Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Current Opinion in Oncology 20:4, 444-453
CrossRef48
Fernanda Milanezi, Silvia Carvalho, Fernando C Schmitt. (2008) EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy. Expert Review of Molecular Diagnostics 8:4, 417-434
CrossRef49
Stephen Hiscox, Robert I Nicholson. (2008) Src inhibitors in breast cancer therapy. Expert Opinion on Therapeutic Targets 12:6, 757-767
CrossRef50
Michelle Shayne, Lodovico Balducci. 2008. Supportive Care for Older Cancer Patients. , 1-34.
CrossRef51
Olivera J. Finn. (2008) Tumor immunology top 10 list. Immunological Reviews 222:1, 5-8
CrossRef52
L. Zelek, P. Escure. (2008) Interventions nutritionnelles et prévention tertiaire des cancers: mythes et réalités. Oncologie 10:4, 238-243
CrossRef53
Quyen D. Chu, Neal Holm, Kerry Byrnes, Benjamin D. Li. (2008) Translational Research in Breast Cancer. Surgical Oncology Clinics of North America 17:2, 421-438
CrossRef54
Wayne A. Beckham, Carmen C. Popescu, Veronica V. Patenaude, Elaine S. Wai, Ivo A. Olivotto. (2007) Is Multibeam IMRT Better Than Standard Treatment for Patients With Left-Sided Breast Cancer?. International Journal of Radiation Oncology*Biology*Physics 69:3, 918-924
CrossRef55
Yang Song, George Y. H. Chi. (2007) A method for testing a prespecified subgroup in clinical trials. Statistics in Medicine 26:19, 3535-3549
CrossRef56
Johann Riedemann, Muhammad Sohail, Valentine M. Macaulay. (2007) Dual silencing of the EGF and type 1 IGF receptors suggests dominance of IGF signaling in human breast cancer cells. Biochemical and Biophysical Research Communications 355:3, 700-706
CrossRef57
Shannon M MacDonald, Alphonse G Taghian. (2007) Partial–breast irradiation: towards a replacement for whole–breast irradiation?. Expert Review of Anticancer Therapy 7:2, 123-134
CrossRef58
Ian Smith, Marion Procter, Richard D Gelber, Sébastien Guillaume, Andrea Feyereislova, Mitch Dowsett, Aron Goldhirsch, Michael Untch, Gabriella Mariani, Jose Baselga, Manfred Kaufmann, David Cameron, Richard Bell, Jonas Bergh, Robert Coleman, Andrew Wardley, Nadia Harbeck, Roberto I Lopez, Peter Mallmann, Karen Gelmon, Nicholas Wilcken, Erik Wist, Pedro Sánchez Rovira, Martine J Piccart-Gebhart. (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. The Lancet 369:9555, 29-36
CrossRef59
Peter H. Johnson, Francisco J. Esteva. (2007) The use of HER2 modulation in the adjuvant setting. Current Oncology Reports 9:1, 9-16
CrossRef60
George Pentheroudakis, Nicholas Pavlidis. (2006) Perspectives for targeted therapies in cancer of unknown primary site. Cancer Treatment Reviews 32:8, 637-644
CrossRef61
Andrea H. Bild, Anil Potti, Joseph R. Nevins. (2006) Linking oncogenic pathways with therapeutic opportunities. Nature Reviews Cancer 6:9, 735-741
CrossRef62
Olivia Pagani, Aron Goldhirsch. (2006) Breast cancer in young women: climbing for progress in care and knowledge. Women's Health 2:5, 717-732
CrossRef63
Jan Norum. (2006) The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer. Expert Opinion on Pharmacotherapy 7:12, 1617-1625
CrossRef64
C. J. Chang, J. H. Chiu, L. M. Tseng, C. H. Chang, T. M. Chien, C. W. Wu, W. Y. Lui. (2006) Modulation of HER2 expression by ferulic acid on human breast cancer MCF7 cells. European Journal of Clinical Investigation 36:8, 588-596
CrossRef65
Sofia Braga, Lissandra dal Lago, Chantal Bernard, Fátima Cardoso, Martine Piccart. (2006) Use of trastuzumab for the treatment of early stage breast cancer. Expert Review of Anticancer Therapy 6:8, 1153-1164
CrossRef66
Emilio Bria, Cecilia Nistico, Federica Cuppone, Paolo Carlini, Mariangela Ciccarese, Michele Milella, Guido Natoli, Edmondo Terzoli, Francesco Cognetti, Diana Giannarelli. (2006) Benefit of taxanes as adjuvant chemotherapy for early breast cancer. Cancer 106:11, 2337-2344
CrossRef67
Piccart-Gebhart, Martine J., . (2006) Anthracyclines and the Tailoring of Treatment for Early Breast Cancer. New England Journal of Medicine 354:20, 2177-2179
Full Text68
Estelle Marrer, Florent Baty, Jeanne Kehren, Salah-Dine Chibout, Martin Brutsche. (2006) Past, present and future of gene expression-tailored therapy for lung cancer. Personalized Medicine 3:2, 165-175
CrossRef69
Sheila A Doggrell. (2006) ‘Simply stunning’ – trastuzumab in HER2-positive breast cancer. Expert Opinion on Pharmacotherapy 7:5, 631-634
CrossRef70
T. B. Y. Liem. (2006) Trastuzumab in combinatie met en na adjuvante chemotherapie bij borstkanker. MFM 44:4, 107-109
CrossRef71
(2006) Trastuzumab in Breast Cancer. New England Journal of Medicine 354:6, 640-644
Full Text72
Manfred Schuster, Andreas Nechansky, Ralf Kircheis. (2006) Cancer immunotherapy. Biotechnology Journal 1:2, 138-147
CrossRef73
Peter Littlejohns. (2006) Trastuzumab for early breast cancer: evolution or revolution?. The Lancet Oncology 7:1, 22-23
CrossRef74
Stefan Paepke, Volker R. Jacobs, Daniela Paepke, Uta Euler, Jens Uwe Blohmer, Mathias Warm, Ralf Ohlinger, Torsten Fischer, Marion Kiechle, Nadia Harbeck. (2006) Critical Appraisal of Primary Systemic Endocrine Therapy in Receptor-Positive Postmenopausal Breast Cancer: An Update. Onkologie 29:5, 210-217
CrossRef75
Greg L Plosker, Susan J Keam. (2006) Trastuzumab. Drugs 66:4, 449-475
CrossRef76
Volker R. Jacobs. (2006) Current Status of Financing and Reimbursement of Trastuzumab (Herceptin<sup>®</sup>) for Adjuvant and Advanced Therapy of Breast Cancer in Germany. Breast Care 1:2, 86-94
CrossRef77
Annette Lebeau. (2006) HER2 Testing in Breast Cancer: Opportunities and Challenges. Breast Care 1:2, 69-76
CrossRef78
(2005) News In Brief. Nature Reviews Drug Discovery 4:12, 948-949
CrossRef
- Letters
